H.R. 2746: Cancer Drug Coverage Parity Act of 2011
Before you vote › Federal bills
H.R. 2746: Cancer Drug Coverage Parity Act of 2011
112th Congress · introduced 2011-08-01 · Health · Latest: Referred to the Subcommittee on Health, Employment, Labor, and Pensions.
federal
Follow this bill, step by step
- Where it came from: introduced 2011-08-01 · official record
- Who proposed it: Rep. Higgins, Brian [D-NY-27] · what a sponsor is
- What happened next: no floor votes in our records yet. Why?
- Where it stands now: Referred to the Subcommittee on Health, Employment, Labor, and Pensions. Not final yet: this can still change. We check for updates every day.
- If it becomes law and spends money: follow the money to money laws, then agencies and contracts and grants.
Official title
Cancer Drug Coverage Parity Act of 2011
Plain summary
Cancer Drug Coverage Parity Act of 2011 - Amends the Employee Retirement Income Security Act of 1974 (ERISA), the Public Health Service Act, and the Internal Revenue Code to require a group or individual health plan providing benefits for intravenously administered or injected anticancer medications to provide no less favorable coverage for prescribed, orally administered anticancer medication that is used to kill or slow the growth of cancerous cells and that has been approved by the Food and Drug Administration (FDA). Applies such requirement to medication that is prescribed based on a finding by the treating physician that the medication is: (1) medically necessary for the purpose of killing or slowing the growth of cancerous cells in accordance with nationally accepted standards of medical practice; (2) clinically appropriate in terms of type, frequency, extent site, and duration; and (3) not primarily for the convenience of the patient, physician, or other health care provider. Permits such coverage to be subject to the same cost-sharing applicable to intravenously administered or injected anticancer medications under the plan. Prohibits a health plan from imposing an increase in out-of-pocket costs, or reclassifying benefits, with respect to anticancer medications. Requires a plan to provide notice to each participant and beneficiary regarding the coverage required under this Act. Prohibits a health plan from taking specified actions to avoid the requirements of this Act. Requires the Medicare Payment Advisory Commission to assess how closing the Medicare part D donut hole affects Medicare coverage for orally administered anticancer medications, with a particular focus on cost and accessibility.
Congressional Research Service summary (Introduced in House), quoted unchanged (nonpartisan). Read the source.
What a vote does
A “Yea” vote
If it passes both chambers and is signed, it becomes law.
A “Nay” vote
If it is not passed, current law stays as it is.
PSI Sci description of the legislative step (not an opinion).
What does this mean? (plain words)
Official text
Cancer Drug Coverage Parity Act of 2011
Source: Congressional Research Service summary (Introduced in House)
AI explanation – may be wrong, check the official text
No AI explanation yet. It takes up to a minute to write and is then saved for everyone.
Limited to a few requests an hour per person.
The strongest published arguments
Arguments for (supporters)
Needs sources: no published arguments on this side yet. We only show items backed by a published source. Suggest one.
Arguments against (opponents)
Needs sources: no published arguments on this side yet. We only show items backed by a published source. Suggest one.
Alternatives
Needs sources: no published alternatives yet (for example a different bill, a law instead of an amendment, or keeping current law). We only show items backed by a published source. Suggest one.
How did my representative vote? · This bill's floor votes
Officials and money
Sponsor: Rep. Higgins, Brian [D-NY-27] · 53 cosponsors
Cost estimate: No cost estimate published yet.
Cosponsors on this site
Judy Chu (D-CA), Betty McCollum (D-MN), Eleanor Holmes Norton (D-DC), Edward J. Markey (D-MA), Gwen Moore (D-WI), Zoe Lofgren (D-CA), Suzanne Bonamici (D-OR), Rosa L. DeLauro (D-CT), Jerrold Nadler (D-NY), Chellie Pingree (D-ME), Janice D. Schakowsky (D-IL), Gary C. Peters (D-MI), Rick Larsen (D-WA), Stephen F. Lynch (D-MA), Paul Tonko (D-NY), James P. McGovern (D-MA), Joe Courtney (D-CT), Diana DeGette (D-CO)
No linked floor roll calls in our collected records yet. This does not mean the bill has never had a vote. Check the official bill history.
Words on this page, explained (2)
- Appropriation
- Money a legislature sets aside by law for a specific purpose. Government agencies may spend public money only as it has been appropriated.
- Securities
- Financial investments that can be bought and sold, such as stocks and bonds.
Plain meanings written from linked sources. All words.
Sources
- Congressional Research Service summary (Introduced in House)
- Congress.gov
- Data: GovInfo BILLSTATUS bulk data (Library of Congress), BILLSTATUS-112hr2746.xml <https://www.govinfo.gov/bulkdata/BILLSTATUS/112/hr>
Record fed-us-cong112-hr2746 · catalog fed-us-congress-bills-cong112 · updated 2026-11-15 by psicol fed-bills-cong112